|
11.Discontinued Operations
The components of loss from discontinued operations as reported in our statements of operations were as follows:
|
|
|
|
|
|
Year ended |
|
|
December 31, |
|
|
2020 |
(In thousands, except per share data) |
|
|
|
Revenue: |
|
|
|
Product revenue |
|
$ |
376 |
Costs and expenses: |
|
|
|
Cost of goods sold |
|
|
1,332 |
Research and development |
|
|
1,917 |
Selling, general and administrative |
|
|
7,224 |
Total costs and expenses |
|
|
10,473 |
Loss from discontinued operations |
|
|
(10,097) |
Other expense, net |
|
|
738 |
Net loss from discontinued operations |
|
$ |
10,835 |
Basic and diluted net loss per common share from discontinued operations |
|
$ |
(2.87) |
Weighted average shares used in computing basic and diluted net loss per common share |
|
|
3,773 |
The following table presents information related to assets and liabilities reported as discontinued operations in our balance sheet:
|
|
|
|
|
|
|
|
|
December 31, |
|
|
2021 |
|
2020 |
|
|
|
(In thousands) |
Prepaid expenses and other current assets |
|
|
12 |
|
|
181 |
Discontinued operations – current assets |
|
$ |
12 |
|
$ |
181 |
|
|
|
|
|
|
|
Accounts payable |
|
$ |
782 |
|
$ |
1,515 |
Accrued clinical trials expenses |
|
|
— |
|
|
80 |
Accrued sales allowances |
|
|
— |
|
|
61 |
Other accrued liabilities |
|
|
362 |
|
|
304 |
Discontinued operations – current liabilities |
|
$ |
1,144 |
|
$ |
1,960 |
During the year ended December 31, 2020 we recognized non-cash stock-based compensation expenses of approximately $0.1 million which is included in discontinued operations.
|